Plain-English translation of NCT06051123 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This trial is testing whether a probiotic formulation—a supplement containing beneficial bacteria—might help people with ALS (amyotrophic lateral sclerosis) and related conditions. Researchers want to see if the medication can affect how the disease progresses and change certain markers in your blood and digestive system. Half of participants will receive the probiotic, and half will receive a placebo (inactive pill) to compare results.
Recent research suggests that gut health may play a role in ALS and similar neurological diseases. This study aims to find out whether this medication could be a supportive treatment option for people newly diagnosed with these conditions.
You likely qualify if…
You likely don't qualify if…
If you enroll, you will be randomly assigned to receive either the probiotic supplement or a placebo for 24 weeks. During this time, you will attend 5 in-person visits and receive 4 phone calls from the research team. At in-person visits, you'll complete questionnaires about your symptoms, provide blood samples, and return stool samples for analysis. The study lasts about 32 weeks total, including a follow-up call after the treatment period ends.
AI-generated summary from trial data · Jul 10, 2026 · Not medical advice
Canada